UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 11, 2006
MYLAN LABORATORIES INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
Pennsylvania
(State or other jurisdiction of
Incorporation)
|
|
1-9114
(Commission File
Number)
|
|
25-1211621
(I.R.S. Employer
Identification No.) |
1500 Corporate Drive
Canonsburg, PA 15317
(Address of principal executive offices)
(724) 514-1800
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
TABLE OF CONTENTS
Item 8.01 — Other Events.
On January 11, 2006, Mylan Laboratories Inc. announced its entry into an agreement with Forest
Laboratories Holdings, Ltd., a subsidiary of Forest Laboratories, Inc., for the commercialization,
development and distribution of Mylan’s novel beta blocker nebivolol in the United States and
Canada.
A
copy of the press release is attached as Exhibit 99.1.
Item 9.01 — Financial Statements and Exhibits.
(c) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
|
|
|
99.1
|
|
Press release dated January 11, 2006. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
MYLAN LABORATORIES INC.
|
|
| Date: January 11, 2006 |
By: |
/s/ Edward J. Borkowski
|
|
| |
|
Edward J. Borkowski |
|
| |
|
Chief Financial Officer |
|